- Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrappedSanofi had hoped the acquisition of Kymab would fill a major hole that will be left as autoimmune juggernaut Dupixent heads toward a patent cliff. Now, another therapy has failed to meet expectations.BioSpace · 25m ago↗ source
- Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotechJennifer Doudna–founded Scribe Therapeutics intends to use the proceeds from the public offering—the first for a gene editing outfit in over two years—to support development of its epigenetic silen…BioSpace · 32m ago↗ source
- Biogen’s Alzheimer’s data spur excitement, confusion about tau-targeting drugsLONDON — One of the most anticipated Alzheimer’s studies in the past few years has created both enthusiasm and confusion, according to conversations Endpoints News recently had with about 20 scient…